Signing a plea agreement that bans hims from the grounds of the University of Virginia and makes him pay court costs, the ...

Heart disease is a type of cardiovascular disease that affects the heart’s structure and function. Several different heart ...

Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday. The company is set to join to the S&P SmallCap 600 this ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

I make the case that investors are not paying up for any GLP1 prospects, or even, for that matter, the actual core business that Hims & Hers (NYSE:HIMS) operates in. I argue that there's a lot ...

As a player in the growing telehealth sector, Hims & Hers Health ($HIMS) has grown significantly, driving its stock up over ...

Hims & Hers Health Q3 2024 revenue projected to surpass estimates by $5M-$10M. Truist consumer survey shows 10% use compounded GLP-1 medications, while 14% prefer branded options. Thursday, The ...

S hares of Hims & Hers (NYSE: HIMS) fell as much as 15% on Thursday after news that Eli Lilly's (NYSE: LLY) GLP-1 drug was taken off the shortage list by the FDA. This could impac ...

Despite semaglutide being the active ingredient in Hims & Hers Health Inc’s (NYSE:HIMS) compounded GLP-1 product, a Truist analyst notes that the recent FDA commentary has reignited investor ...

Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $17.66 which represents a slight increase of $0.53 or 3.09% from the prior close of $17.13. The stock opened at $17.55 and ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our P/B Growth Investor model based on the published ...